These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28558898)

  • 1. Aripiprazole and impulse-control disorders in high-risk patients.
    Mohan T; Dolan S; Mohan R; Dawson J
    Asian J Psychiatr; 2017 Jun; 27():67-68. PubMed ID: 28558898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole induced Impulse Control Disorders: Where do we stand?
    Mahapatra A; Sharma P; Sagar R
    Asian J Psychiatr; 2016 Oct; 23():128-130. PubMed ID: 27969070
    [No Abstract]   [Full Text] [Related]  

  • 3. Aripiprazole and Impulse-Control Disorders: A Recent FDA Warning and a Case Report.
    Dhillon R; Bastiampillai T; Cao CZ; Eckert TG; Tibrewal P
    Prim Care Companion CNS Disord; 2017 Jan; 19(1):. PubMed ID: 28102975
    [No Abstract]   [Full Text] [Related]  

  • 4. Aripiprazole: impulse control disorders. Pathological gambling.
    Prescrire Int; 2016 Nov; 25(176):271. PubMed ID: 30730124
    [No Abstract]   [Full Text] [Related]  

  • 5. Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole.
    Peterson E; Forlano R
    Australas Psychiatry; 2017 Dec; 25(6):614-616. PubMed ID: 28696131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersexuality induced by Aripiprazole: Two case reports and review of the literature.
    Reddy B; Ali M; Guruprasad S; Das S
    Asian J Psychiatr; 2018 Dec; 38():57-59. PubMed ID: 29107566
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathological gambling and the treatment of psychosis with aripiprazole: case reports.
    Smith N; Kitchenham N; Bowden-Jones H
    Br J Psychiatry; 2011 Aug; 199(2):158-9. PubMed ID: 21804151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study.
    Etminan M; Sodhi M; Samii A; Procyshyn RM; Guo M; Carleton BC
    J Clin Psychopharmacol; 2017 Feb; 37(1):102-104. PubMed ID: 27930495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting.
    Kodama M; Hamamura T
    Int J Neuropsychopharmacol; 2010 May; 13(4):549-51. PubMed ID: 19917149
    [No Abstract]   [Full Text] [Related]  

  • 10. Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?
    Lertxundi U; Hernandez R; Medrano J; Domingo-Echaburu S; Garcia M; Aguirre C
    Int Clin Psychopharmacol; 2018 Jan; 33(1):56-58. PubMed ID: 28777129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists: A Retrospective Cohort Study.
    Sodhi M; Etminan M; Carleton B; Samii A
    J Clin Psychopharmacol; 2019; 39(6):675-676. PubMed ID: 31688453
    [No Abstract]   [Full Text] [Related]  

  • 12. Quetiapine-associated pathological stealing in an adolescent girl.
    Huang WL; Chang LR
    J Neuropsychiatry Clin Neurosci; 2013; 25(1):E53. PubMed ID: 23487235
    [No Abstract]   [Full Text] [Related]  

  • 13. Two Adolescent Cases of Psychotropic-Related Nonaffective Oniomania.
    Naguy A; Abdelhakim W; Al-Tajali A
    J Child Adolesc Psychopharmacol; 2018 May; 28(4):295-296. PubMed ID: 29240460
    [No Abstract]   [Full Text] [Related]  

  • 14. Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: A systematic review of case reports.
    Akbari M; Jamshidi S; Sheikhi S; Alijani F; Kafshchi P; Taylor D
    Psychopharmacology (Berl); 2024 Feb; 241(2):209-223. PubMed ID: 38227009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pisa Syndrome and Aripiprazole.
    Smith C; Gwynn N; Lindenmayer JP
    J Clin Psychopharmacol; 2020; 40(1):99-101. PubMed ID: 31834091
    [No Abstract]   [Full Text] [Related]  

  • 16. Aripiprazole and Other Third-Generation Antipsychotics as a Risk Factor for Impulse Control Disorders: A Systematic Review and Meta-Analysis.
    Williams BD; Lee K; Ewah SO; Neelam K
    J Clin Psychopharmacol; 2024 Jan-Feb 01; 44(1):39-48. PubMed ID: 38011021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole-induced tardive dyskinesia in patients with schizophrenia: A case report of twins.
    She S; Kuang Q; Zheng Y
    Schizophr Res; 2018 Jul; 197():564-565. PubMed ID: 29128325
    [No Abstract]   [Full Text] [Related]  

  • 18. Aripiprazole-induced Asymptomatic Hypertension: A Case Report.
    Seven H; Ayhan MG; Kürkcü A; Özbek S; Eren İ
    Psychopharmacol Bull; 2017 May; 47(2):53-56. PubMed ID: 28626272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
    Fusaroli M; Raschi E; Giunchi V; Menchetti M; Rimondini Giorgini R; De Ponti F; Poluzzi E
    Int J Neuropsychopharmacol; 2022 Sep; 25(9):727-736. PubMed ID: 35639870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
    Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
    Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.